COVID-19: A Global health concern

Camtech's test kits are manufactured in Singapore under ISO 13485:2016

COVID-19 Antigen Rapid Test Kit

Early detection of COVID-19 cases

Reliable identification of SARS-CoV-2 viral particles within the first week of the onset of symptoms or in certain asymptomatic cases.

Easy to read and evaluate

With a clear and visible signal, the results are easy to understand based on the presence or absence of the Control (C) and Test (T) lines.

Rapid point-of-care testing

Besides the test card, the kit also contains all the necessary components for a convenient and fast testing procedure.

Certified Quality Standards

Manufactured under ISO13485:2016, received CE Mark and provisional authorisation from Health Sciences Authority (Singapore).

COVID-19 Antigen Rapid Self-Test Kit

Home-based testing

A convenient and safe option to perform SARS-CoV-2 testing privately at your home for yourself or family members.

Complete kit

The self testing kit includes everything that you need to perform the assay: 2 sets of test cards, sampling swabs, tubes with buffer solution and instructions.

Easy sampling

The self-testing kit brings accurate results from nasal (anterior nares) swabs. This type of sample is simple to take from the front of the nose without having the need to perform deep naso or oropharyngeal swabbing.

Peace of mind

With frequent and regular testing further spread of the virus can be reduced and employees can feel safer to return to work.

COVID-19 IgM/IgG Rapid Antibody Test Kit

Fast detection of COVID-19

The test can be performed in 10 minutes from patients' whole blood, serum or plasma.

Proven clinical performance

Excellent diagnostic performance, as demonstrated in a peer-reviewed clinical study completed at the Federal University of Parana (Brazil).

Affordable testing expenses

Since highly trained personnel or expensive equipment is not needed, the cost of testing is relatively low.

Tested and used worldwide

Camtech has provided antibody testing kits to several countries across the globe to identify COVID-19 hotspots.

ProTect™ COVID-19 RT-qPCR Kit

by JN Medsys

Tested and reliable protocol

The kit is compatible with the US CDC protocol and received provisional authorisation from Health Sciences Authority (Singapore).

Early detection

The amplification of viral nucleic acids provides detection at very early stages of the infection, even before symptoms occur.

Wide range of suitable samples

Viral particles are present in the throat and sputum. Nasopharingeal swabs make it easy to acquire specimens.

Monkeypox Antigen Rapid Test Kit

Monkeypox virus detection

The test device is an immunochromatographic assay for the direct and qualitative detection of Monkeypox antigen

Sample options

The test kit can evaluate respiratory samples and swabs from skin lesions

Clinically evaluated

Clinical studies indicated 95.5% senstivity and 100% specificity

Rapid results

Including simple sample preparation, results can be obtained in less than 20 minutes.

Monkeypox virus PCR detection kit

Intended use

Designed to detect DNA from Monkeypox virus in specimens, such as serum or plasma, vesicular skin lesions collected from individuals

Test principle

Based on real-time PCR fluorescent technology. Specific primers and fluorescent probes to the conserved regions to the virus have were designed for highly specific detection

Kit delivery formats

24 tests/box, 48 tests/box and 96 tests/box

Rapid and accurate

The whole process from extraction until amplicifation takes ~45 minutes, while the sensitivity remains high at 500 copies / mL.

Specimen Collection Kit

by JN Medsys

Intended use

For the collection of cells and microbiological specimen from the nasopharyngeal area, followed by storage in the medium for transport to the laboratory for analysis.

Contents of the kit

1 x flocked swab and 1 x viral universal transport medium (2ml)
100 per pack

Extended shelf life

The collection kit can be stored at 15-30ºC for 12 months.

For COVID-19 Screening

This samples collection kit includes the basic components that is needed for collecting nasopharyngeal swabs for RT-qPCR analysis to determine SARS-CoV-2 infection.

Why is testing important?

We want to know the total number of people infected with COVID-19. To know this, it is necessary to have widespread testing.

When testing is too low we do not have a clear picture of what is going on.

Testing is crucial as it allows the infected person to avoid infecting others and to quickly receive the care they need. And it is crucial for all of us to understand the prevalence of the disease, to understand how the disease evolves, and to allow us to take evidence-based decisions for counter measures that slow down the spread of the disease.


Research partnerships

Camtech™ works together with A*STAR, Singapore's Agency for Science, Technology and Research, in developing more specific and targeted antibody tests for IgM/IgG.

Frequently asked questions

There are several approaches that can be used to identify an infection, these focus on detecting either viral proteins (Early detection), viral nucleotide sequences (Early detection) or antibodies (Later detection) raised against specific viral components.

  1. Quantitative Polymerase Chain Reaction (qPCR) is used for detecting specific nucleotide sequences of the virus. These nucleotide sequences encode proteins that are crucial for the virus to hijack cellular mechanisms to drive the production of new viral particles. These nucleotide sequences can be isolated and amplified using PCR, and further quantified using fluorescent probes using qPCR systems.

  2. Enzyme-linked immunosorbent assays (ELISAs) provide a readout of antigen-antibody interactions.
    In the case of IgM/IgG antibody tests, patient antibodies are “sandwiched” between the deposited viral protein of interest and reporter antibodies, so that any active patient antibodies are detected.
    Antigen tests work similarly, but in that case the Antigen-specific capture antibody is deposited and the viral particles get captured between this and the labelled antigen-specific antibody. The labeling method can produce a visible signal (immunogold) or a fluorescent signal, that is revealed under UV-light. Rapid test kits, or Lateral Flow Assays (LFA) are based on the same principles, but are packaged into an easy to use, point-of-care format.

  3. Neutralization tests can indicate whether the patient has active, functional antibodies to the pathogen in question by measuring how much the patient antibodies can inhibit viral growth in the lab.

The incubation period for the infection can vary from 2 to 14 days. This variation makes it difficult to pinpoint a timeframe when a person was infected and could vary by the same amount as the incubation period.

Patient antibodies (IgM/IgG) against the virus particles, which is tested by the COVID-19 IgM/IgG Rapid test kit, only appear after symptoms arise (1-3 weeks). The recommended time frame is 7 days after the onset of symptoms (87% Sensitivity), when IgMs and IgGs can be visually detected using the LFA kit. However, sensitivity improves over time and is over 95% 10 days post symptoms. Antigen Rapid test or RT-qPCR test is recommended to identify acute COVID-19.

The COVID-19 Viral Antigen Detection kit detects the Nucleocapsid (N) protein of the SARS-CoV-2 virus from naso- or oropharyngeal swabs, while the ProTect™ COVID-19 RT-qPCR kit is based on the direct molecular diagnostics of the virus RNA. Based on other respiratory viral infections it is estimated that the detectable viral load is present after 3-4 days of infection, which typically coincides with the first few days of the onset of symptoms. Rapid antigen test kits can reliably identify patients with high viral load during the first 7 days after the onset of symptoms, while the RT-PCR test can still detect viral RNA for an extended period of time (2-3 weeks after infection).

Please refer to the individual brochures for accuracy information.
Please get in touch with us through the Contact form indicating the type and volume of the testing kits needed.
The Camtech™ COVID-19 IgM/IgG test has been designed to minimise the likelihood of false positive test results. With regards to serological testing the FDA specifies that true negative samples should have been from patients prior to the SARS-CoV-2 outbreak (pre-pandemic samples) as RT-qPCR is not an effective way of ruling out past infections. However, If the Camtech™ IgM/IgG test gives you a positive result which is in contrast with a negative RT-qPCR result there may be several factors to consider, these include but are not limited to.

  • RT-qPCR may be negative due to the lack of viral nucleotides in patients who have recovered from SARS-CoV-2, however, antibodies against the infection may persist, resulting in a positive Antibody test.

  • Cross-reactivity with non- SARS-CoV-2 associated circulating antibodies (i.e. Influenza).

  • The RT-qPCR result may be a false negative.

  • Poor interpretation of results, potentially due to use by non-qualified medical professionals.
Positive antigen kit result: If you have a positive result it is very likely that you have the proteins from the virus that was found in your sample. The antigens are generally detectable in the specimens from the upper respiratory tract, nevertheless, clinical correlation with patient history and the necessary diagnostic information is required to determine the infection status. Positive results also do not rule out bacterial infection or cross-infections with other bacteria or viruses.

Negative antigen kit result: A negative result indicates that the antigens from SARS-CoV-2 was not present in the specimen. It also means that the viral load was below the limit of detection. The amount of antigen in a sample is known to decrease with the increase in the duration of the illness. However, a negative test should not be used as the only basis of treatment or patient management as samples collected beyond 7 days post symptom should be treated as presumptive and confirmed with a molecular assay.
The Camtech COVID-19 Rapid Antigen Test kit has been evaluated with recombinant target antigen protein that correspond to the mutations identified in the broadly circulating variants, such as Alpha, Beta, Gamma, Delta and Omicron. The results determined that the sensitivity of Antigen kit remains high. This is expected as the detecting antibodies used in the Antigen kits are targeting a more conserved protein of the SARS-CoV-2 virus, which has not mutated significantly in the variants evolved after the original Wuhan strain.
The sensitivity to the Alpha variant (B.1.1.7) has been confirmed using heat inactivated virus samples as well. Additionally, based on the prevalence of the SARS-CoV-2 virus strains during the clinical tests we expect that the performance towards the Delta and Omicron strains is idenical compared to the earlier variants.

Technical information

  • All Camtech™ tests kits are manufactured under ISO 13485.

  • Both the COVID-19 Viral Antigen Detection Kit and the COVID-19 IgM/IgG Rapid Antibody Test Kit have obtained provisional authorisation from the Singapore Health Sciences Authority (HSA), have been approved by the regulatory authorities in several countries and received a Declaration of conformity from the EU (CE IVD).

  • Camtech™ carried out clinical studies in several continents, which have validated the high sensitivity and specificity of the kits. The field studies indicated that the kit's performance is stable across all variants.

  • The ProTect™ COVID-19 RT-qPCR Kit has obtained provisional authorisation from the Singapore Health Sciences Authority (HSA) and has a declaration of conformity from the EU (CE IVD).

  • Please note that our products are not to be used by consumers or marketed over the counter or directly to consumers and are only for use by certified healthcare establishments or where administered by a trained healthcare professional and in accordance to the "Instructions for Use" of the product.

  • Results from the rapid test kits should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status, particularly in those who have been in contact with virus carriers. Follow-up testing with a molecular diagnostic method should be considered to rule out infection in these individuals.

  • Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

  • Not for the screening of donated blood.

Contact Us

  • For Home use kits or OTC enquiries please call us at: +65 6265 1817

  • For larger orders, we have a Minimum Order Quantity. For such enquiries, please contact us on the form below.

  • If you are a hospital/ clinical research institute and would like to undertake a research collaboration on patient samples kindly reach us below with your project description.

Camtech™ Privacy Policy